Market revenue in 2023 | USD 89.8 million |
Market revenue in 2030 | USD 126.9 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.92% in 2023. Horizon Databook has segmented the Brazil pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil has the largest population in Latin America. According to the data published by Cancer Today, in 2022, Brazil accounted for the largest share (35.8%) of cancer cases in Latin America. Hence, pancreatic cancer incidence in the country is high, which has led to increased usage of various novel cancer screening tools, such as liquid biopsy and gene panel testing.
However, it may take some time for liquid biopsy to be used widely in the country due to the expensive testing procedure and very limited availability of skilled professionals. Several professionals in Brazil consider solid tumor biopsy the gold standard, as it offers a deep analysis of cancer mutation.
However, in the past few years, Brazil has witnessed high growth in the adoption of liquid biopsy techniques due to increasing collaborations between key players and various initiatives being undertaken by several organizations for cancer care.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Brazil pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account